CHGA and type 1 diabetes mellitus: Therefore, to determine whether longitudinal changes in serum CHGA would continue to mirror therapeutic effects or disease progression over a longer period of time, we measured CHGA levels in a small number of study subjects with T1D who had received verapamil in year 1 and continued the treatment for a second year after diagnosis, as well as in control study participants who had never received verapamil.